A promising combination therapy for triple-negative breast cancer

Pinterest LinkedIn Tumblr +

Researchers at Baylor College of Medicine, USA, and collaborating institutions have identified a combination therapy for treating triple-negative breast cancer (TNBC) that results in durable tumour regression in an animal model of the condition.

The combination therapy attacked the tumour on two fronts. On one side, the chemotherapy drug cyclophosphamide eliminated tumour cells, while on the other front, another drug inhibited tumour-associated macrophages, which block the body’s immune response against the tumour.

This two-front strategy effectively treated several highly aggressive TNBC primary tumours and metastasis. The study appeared in the journal Cancer Research.

“TNBC is an aggressive subtype of breast cancer with an overall poorer prognosis than other breast cancer subtypes,” said co-corresponding author Dr. Jeffrey Rosen, Distinguished Service Professor of molecular and cellular biology and in the Dan L Duncan Comprehensive Cancer Center at Baylor.

The team had previously shown in animal models that although treating the tumours with cyclophosphamide eliminated the cancer initially, the disease came back eventually. A closer look into the tumour microenvironment revealed that the tumours that returned typically had many macrophages.

We were excited to see that the tumours did not return a month after stopping the combination therapy. Swarnima Singh

“In this study, we explored the possibility that eliminating both the tumour cells and the macrophages would improve the chances of eliminating the tumour for a longer period of time,” said Swarnima Singh, first author of the paper and a student in Baylor’s graduate school of biomedical sciences working jointly in the Rosen and Zhang laboratories.

“We eliminated macrophages with either a small molecule inhibitor or a monoclonal antibody toward CSF1R, a marker on these cells.”

For several months, the team treated the tumours with a combination of drugs. Then, they stopped treatment and followed up tumour progression in the treated animals.

“We were very encouraged by the results,” Singh said. “Typically, a month after stopping single-drug treatment, the tumours returned. We were excited to see that the tumours did not return a month after stopping the combination therapy. We observed a durable response in two animal models of TNBC.”

Interestingly, the animals with a durable response were able to prevent new tumours from growing. “We challenged these animals with fresh tumour cells, and 40% of them rejected them.

The tumours did not grow. This suggested that the animals had immune memory capable of fighting back new tumour growth. In addition to primary tumours, we also treated lung tumour metastasis with combination therapy and found that it also eliminated cancer growth effectively.”

Rosen and his colleagues also investigated how the tumour microenvironment had changed in the animals with a durable response.

“We found that when we treated the tumours with one of the two drugs, which did not produce a durable response, immune B and T cells involved in fighting the tumour did not enter it, they remained in the periphery of the tumour mass,” said co-corresponding author Dr. Xiang H.F. Zhang, interim director of the Lester and Sue Smith Breast Center and William T. Butler, M.D., Endowed Chair for Distinguished Faculty. Zhang also is professor of molecular and cellular biology, a member of the Dan L Duncan Comprehensive Cancer Center and a McNair Scholar at Baylor.

On the other hand, after combination therapy, both B and T cells entered the tumour mass and remained close to each other, suggesting they were interacting to mediate tumour elimination in a durable manner.

Looking to translate these findings into the clinic, the researchers investigated whether the macrophage signature they had observed in the animal models also was present in TNBC from patients. “Indeed, tumours from patients with the worse prognosis also presented high numbers of macrophages,” Rosen said. “We think this signature can help us identify patients who might be candidates for combination therapy.”

The researchers are planning to conduct a clinical trial to assess the value of their approach in treating human TNBC.


Source: Baylor College of Medicine

Share.

About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.